A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. II. Update and analysis of risk factors.
A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. II. Update and analysis of risk factors.
复制标题
增殖性镰状细胞性视网膜病的饲养血管光凝的随机临床试验。
DOI：
10.1016/s0161-6420(84)34121-5
复制
发表时间：
1984
期刊：
影响因子：
13.7
通讯作者：
Serjeant,G
中科院分区：
文献类型：
--
作者：
Condon,P;Jampol,LM;Farber,MD;Rabb,M;Serjeant,G
一项关于增生性镰状细胞性视网膜病变的饲养血管光凝治疗的随机前瞻性试验的患者随访显示，光凝可有效预防玻璃体出血和玻璃体出血所致视力丧失。此外，光凝眼中所有原因导致的视力丧失的减少接近统计学显著性。对对照眼的分析表明，玻璃体积血的发生有三个独立的风险因素：（1）SC基因型的存在，（2）初始评估时玻璃体积血的存在，（3）灌注新生血管大于60°的存在。
Follow-up of patients enrolled in a randomized prospective trial of feeder vessel photocoagulation for proliferative sickle cell retinopathy has shown that photocoagulation is effective in preventing vitreous hemorrhage and visual loss from vitreous hemorrhage. In addition, a reduction of visual loss from all causes in photocoagulated eyes approaches statistical significance. Analysis of control eyes shows that there are three independent risk factors for the occurrence of vitreous hemorrhage: (1) the presence of the SC genotype, (2) the presence of vitreous blood at the initial evaluation and, (3) the presence of greater than 60° of perfused neovascularization.